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Abstract
Background: Histopathology is the standard method for cancer diagnosis and grading to assess aggressiveness in
clinical biopsies. Molecular biomarkers have also been described that are associated with cancer aggressiveness,
however, the portion of tissue analyzed is often processed in a manner that is destructive to the tissue. We present
here a new method for performing analysis of small molecule biomarkers and histology in exactly the same biopsy
tissue.
Methods: Prostate needle biopsies were taken from surgical prostatectomy specimens and first fixed, each in a
separate vial, in 2.5 ml of 80% methanol:water. The biopsies were fixed for 24 hrs at room temperature and then
removed and post-processed using a non-formalin-based fixative (UMFIX), embedded, and analyzed by
hematoxylin and eosin (H&E) and by immunohistochemical (IHC) staining. The retained alcohol pre-fixative was
analyzed for small molecule biomarkers by mass spectrometry.
Results: H&E analysis was successful following the pre-fixation in 80% methanol. The presence or absence of
tumor could be readily determined for all 96 biopsies analyzed. A subset of biopsy sections was analyzed by IHC,
and cancerous and non-cancerous regions could be readily visualized by PIN4 staining. To demonstrate the
suitability for analysis of small molecule biomarkers, 28 of the alcohol extracts were analyzed using a mass
spectrometry-based metabolomics platform. All extracts tested yielded successful metabolite profiles. 260 named
biochemical compounds were detected in the alcohol extracts. A comparison of the relative levels of compounds
in cancer containing vs. non-cancer containing biopsies showed differences for 83 of the compounds. A
comparison of the results with prior published reports showed good agreement between the current method and
prior reported biomarker discovery methods that involve tissue destructive methods.
Conclusions: The Molecular Preservation by Extraction and Fixation (mPREF) method allows for the analysis of
small molecule biomarkers from exactly the same tissue that is processed for histopathology.
Background
Histopathology is the standard method for cancer diag-
nosis and grading to assess aggressiveness in clinical
biopsies. Molecular biomarkers have also been described
that are associated with cancer aggressiveness. A long-
standing problem is that while intact tissue is required
for microscopic examination for histology, biomarker
detection often requires tissue disruption [1] meaning
that the histopathology and molecular analysis are not
performed on the same exact tissue. Immunohistochem-
istry (IHC) and fluorescence in-situ hybridization (FISH)
were introduced to detect protein and DNA biomarkers
in intact tissues, and although these were major techno-
logical innovations, IHC in particular is not quantitative
and is affected by many variables [2-4]. These methods
applied to intact tissue sections are also very difficult to
multiplex so that only one or a few biomarker targets
can be measured. Because IHC and FISH are interpreted
by microscopic examination, results can also vary
between observers [5]. Therefore, analysis of biomarkers
in intact tissue remains a choke-point for translational
medicine. This is particularly evident when limited
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any medium, provided the original work is properly cited.amounts of tissue are available, as is often the case when
small biopsies are obtained by image guided methods in
the outpatient setting. Submitting one such core for his-
topathology and another separate core for quantitative
molecular methods is not desirable as it is difficult to be
certain that both portions of tissue contained disease.
This work describes a method that allows for combin-
ing histopathology and small molecule biomarker analy-
sis from the same tissue specimen using a fixative
solution which historically is only discarded. The
method, Molecular Preservation by Extraction and Fixa-
tion (mPREF), substitutes alcohol for formalin as a tis-
sue fixative, leading to extraction of small molecules
into the alcohol from the tissue (Figure 1). Formalin has
been used for tissue fixationi np a t h o l o g yf o ro v e r1 0 0
years. Form alin’sf i x a t i v ef e a t u r e sw e r ea c c i d e n t a l l yd i s -
covered by Ferdinand Blum during experimental studies
as a potential disinfectant at the end of the 19
th century
[6]. The toxic properties of formalin are also well
described including carcinogenicity, and acute and
chronic exposure related illness [7]. Additionally, it is
well known that formaldehyde is largely destructive to
small molecules of increasing value to understanding
disease states. Using an alcohol extraction, small mole-
cules can be assayed in the biopsy fixative solution while
the exact same tissue is processed for histology. Metabo-
lomics is a method by which low molecular weight (<2
kD) biochemical compounds (e.g. metabolites) are
extracted, detected, and measured. We describe a simple
method for combining histology and metabolomics to
characterize alcohol extractable small molecules from
tissues. The use of alcohol as a tissue fixative is not
new, and the accumulated literature suggests that
macromolecules (DNA, RNA, and proteins) remain
intact in tissue thus processed [8-10]. Therefore, IHC
and FISH can be performed on alcohol extracted tissue,
and the histopathologist and molecular pathologist can
continue to perform the same immunohistochemical
and molecular assays now performed on sections of par-
affin embedded tissue.
An example for the use of the mPREF methodology is
presented for prostate cancer biopsy tissue. Prostate
cancer is a significant health concern with an estimated
over 200,000 new cases each year in the United States,
and although screening for early detection is routinely
performed, over 30,000 men die each year from the dis-
ease [11]. Prostate cancer is one of the cancers for
which screening in asymptomatic populations is cur-
rently recommended, and as such, a number of early
stage cancers are detected [12-14]. It is well recognized
that prostate cancer is a heterogeneous disease [15] and
even employing all diagnostic modalities available today,
it remains difficult to determine with surety which
tumors are indolent, and which are aggressive and have
the potential to metastasize. As a result, clinical practice
seeks to balance the relative risks of treatments with
those of expectant management programs [16,17]. Mole-
cular biomarkers are currently being investigated to help
better differentiate more indolent from more aggressive
disease. These include the identification of biomarkers
based on nucleic acids [18-24], proteins [25,26], metabo-
lites [27-33], advanced histomorphology [25,26], and cir-
culating tumor cells [34-38].
Results
Histology and Immunohistochemistry
H&E analysis was successful following the pre-fixation in
80% methanol. The presence or absence of tumor could
be readily determined for all 96 biopsies analyzed. A
montage showing different fields of representative H&E
stained histological sections is shown in Figure 2. Pre-
vious studies comparing alcohol fixed tissues to formalin
fixed tissues focused on nuclear and cellular morphology,
architecture, and staining characteristics [10]. We find
that each of these features is acceptable in prostate tis-
sues fixed in aqueous alcohol and the alcohol fixation
does not interfere with the IHC using the PIN4 cocktail
stain (Figure 2). The comparison is qualitative, and there
are differences in appearance of alcohol versus formalin
fixed tissues including finer nuclear chromatin detail in
alcohol. The differences are subtle, however, in most
cases, we are confident that trained pathologists can both
discern the difference between formalin fixed and alcohol
fixed tissues. Further, we are also confident that alcohol
fixed tissues can be used for histological diagnosis. We
routinely use aqueous alcohol for prostate, bladder, and
kidney tissues processed in our clinical facility (Sentara
Norfolk General Hospital, Norfolk, Virginia).
Analysis of metabolites in biopsy extracts
To demonstrate the suitability of mPREF for the analysis
of small molecule biomarkers, 28 of the alcohol extracts
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Figure 1 Molecular Preservation by Extraction and Fixation
(mPREF) method. The mPREF work flow showing, left to right,
immersion of tissue biopsy (with small molecules) in alcohol and
subsequent removal of the tissue for processing for histology. The
remaining alcohol containing the extracted small molecules is
capped and stored for subsequent analysis.
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metabolomics platform. 260 named biochemical com-
pounds were detected in the alcohol extracts. A compar-
ison of the relative levels (by ion counts) of compounds
in cancer containing vs. non-cancer containing biopsies
showed changed levels of 83 of the compounds
(matched pairs t-test, p < .05) with 82 of the 83 com-
pounds showing an increased level in extracts from the
cancer containing biopsies (Table 1). Eighteen of the 20
common amino acids and a number of long chain fatty
acids and phospholipids were increased, possibly indica-
tive of a higher metabolic state in the cancer containing
biopsy tissues as compared with non-cancer containing
biopsy tissues.
It was not feasible to obtain biopsies with the same
amount of tumor present in each of the needle biopsies.
The average percent of tumor in the biopsies for
pathology T3 tumors was higher than that of the T2
tumors (60% for T3 biopsies, and 36% for the T2 biop-
sies). To determine the relationship of compound level
as a function of the percent tumor in the biopsy, the
levels for one of the amino acids, alanine, that has been
previously reported to increase in prostate cancer [28]
was plotted as a function of the percent tumor mea-
sured in the biopsy. Figure 3 shows that there is not a
strong relationship between percent of tumor in the
biopsy and the level of alanine. Similar results were
observed for other amino acids (not shown).
The metabolomics method used in this study is
semi-quantitative and reports relative levels for each of
the compounds as ion counts (absolute levels of meta-
bolites are not determined using this method). The
highest fold changes observed for the 83 compounds
were approximately 4- to 6-fold with the following
Figure 2 Composite panel showing H&E and PIN4 IHC of biopsies processed with mPREF. Histology of prostate biopsies processed using
the mPREF method. The figure compares histopathology of benign glands (top row) to malignant glands (middle row) stained with H&E. 4
micron sections were prepared. Each frame is from a separate subject. The bottom row shows IHC staining for PIN-4 cocktail wherein brown
basal staining is present in benign prostatic glands and absent in tumor glands. In reciprocal fashion, racemase staining, indicated by red
pigment, is present in malignant glands and absent from normal glands. Each frame is from a different subject.
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Biochemical
Group
Biochemical Pathway Compound Fold change Cancer/No-
cancer
p-
value
q-
value
Amino acid Alanine, aspartate metabolism alanine 1.6 0.013 0.049
aspartate 2.2 0.013 0.049
N-acetylaspartate 6.1 0.020 0.049
Butanoate metabolism 2-aminobutyrate 1.8 0.014 0.049
Cysteine, methionine metabolism cysteine 4.6 0.049 0.061
cystine 2.9 0.024 0.049
methionine 3.6 0.012 0.049
S-adenosylhomocysteine 1.6 0.004 0.049
Glutamate metabolism glutamate 2.4 0.019 0.049
N-acetyl-aspartyl-glutamate 1.9 0.014 0.049
Glutathione metabolism 5-oxoproline 1.9 0.017 0.049
cysteine-glutathione disulfide 3.4 0.043 0.060
Glycine, serine, threonine
metabolism
betaine 2.3 0.022 0.049
glycine 2.6 0.020 0.049
serine 2.1 0.009 0.049
threonine 1.4 0.003 0.049
Histidine metabolism histidine 1.5 0.001 0.043
Lysine metabolism 2-aminoadipate 2.1 0.021 0.049
lysine 2.3 0.027 0.052
Phenylalanine, tyrosine metabolism phenylalanine 1.8 0.011 0.049
tyrosine 1.9 0.014 0.049
Tryptophan metabolism tryptophan 1.9 0.010 0.049
Urea cycle; arginine, proline
metabolism
arginine 1.2 0.033 0.056
ornithine 2.7 0.019 0.049
proline 1.6 0.007 0.049
trans-4-hydroxyproline 2.1 0.036 0.056
Valine, leucine, isoleucine
metabolism
isoleucine 1.8 0.016 0.049
leucine 1.8 0.010 0.049
valine 1.6 0.016 0.049
Carbohydrate Aminosugars N-acetylglucosamine 5.9 0.028 0.052
Glycolysis glucose 1-phosphate 0.7 0.033 0.056
Pentose metabolism ribose 2.7 0.018 0.049
Cofactors and
vitamins
Pantothenate pantothenate 2.3 0.008 0.049
Tocopherol alpha-tocopherol 2.2 0.041 0.058
Energy Krebs cycle fumarate 2.1 0.007 0.049
malate 2.0 0.006 0.049
succinate 1.6 0.009 0.049
succinylcarnitine 2.2 0.041 0.058
Lipid Carnitine metabolism 3-dehydrocarnitine 1.9 0.023 0.049
acetylcarnitine 1.6 0.015 0.049
carnitine 1.7 0.033 0.056
deoxycarnitine 1.6 0.010 0.049
Essential fatty acid docosahexaenoate 3.2 0.046 0.060
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biopsy extracts: cysteine, dihomo-linoleate, docosapen-
taenoate, N-acetylaspartate, N-acetylglucosamine, ura-
cil, xanthine, and 1-stearoylglycerophosphoinositol
(Table 1).
The purpose of this study was primarily to demon-
strate that histopathology and small molecule biomarker
marker studies could be performed on the same exact
tissue specimen. To also determine whether the tissue
non-destructive mPREF method results were consistent
Table 1 (Continued)
docosapentaenoate 4.2 0.018 0.049
Fatty acid metabolism butyrylcarnitine 1.9 0.012 0.049
propionylcarnitine 2.0 0.036 0.056
4-hydroxybutyrate 2.1 0.023 0.049
Glycerolipid metabolism choline 1.7 0.004 0.049
ethanolamine 3.4 0.039 0.056
glycerol 1.9 0.047 0.060
glycerophosphorylcholine 1.8 0.022 0.049
Long chain fatty acid 10-nonadecenoate 2.8 0.036 0.056
dihomo-linoleate 4.8 0.038 0.056
eicosenoate 3.0 0.013 0.049
myristoleate 1.7 0.045 0.060
oleate 2.1 0.038 0.056
Lysolipid 1-
arachidonoylglycerophosphoethanolamine
1.9 0.007 0.049
1-arachidonoylglycerophosphoinositol 2.2 0.006 0.049
1-linoleoylglycerophosphoethanolamine 2.6 0.020 0.049
1-oleoylglycerophosphoethanolamine 2.4 0.007 0.049
1-oleoylglycerophosphoinositol 3.7 0.035 0.056
1-oleoylglycerophosphoserine 2.6 0.022 0.049
1-palmitoylglycerophosphoinositol 3.3 0.047 0.060
1-stearoylglycerophosphoethanolamine 2.2 0.019 0.049
1-stearoylglycerophosphoinositol 4.0 0.044 0.060
2-oleoylglycerophosphoethanolamine 2.4 0.004 0.049
2-palmitoylglycerophosphoethanolamine 2.1 0.027 0.052
Medium chain fatty acid caprylate 1.2 0.046 0.060
Nucleotide Purine and pyrimidine methylphosphate 2.2 0.018 0.049
Purine metabolism, hypoxanthine/
inosine
hypoxanthine 2.2 0.004 0.049
inosine 1.6 0.026 0.052
xanthine 5.2 0.030 0.055
xanthosine 2.0 0.014 0.055
Purine metabolism adenine 1.8 0.038 0.056
guanosine 1.6 0.035 0.056
Pyrimidine metabolism cytidine 1.9 0.034 0.056
pseudouridine 1.3 0.024 0.049
uracil 4.0 0.003 0.049
uridine 1.9 0.008 0.049
Peptide gammaglutamyl gamma-glutamylglutamate 2.3 0.032 0.056
gamma-glutamylglutamine 3.3 0.033 0.056
Other Benzoate metabolism benzoate 1.4 0.045 0.060
Other glycerol 2-phosphate 2.1 0.028 0.052
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methods, a subset of metabolites was examined based
on published reports of small molecule candidate bio-
markers that change with the degree of aggressiveness
of prostate cancer. Although the number of biopsy
extracts analyzed by mass spectrometry were limited in
number, the results were consistent with prior published
data with similar numbers of prostatectomy tissues as
described below.
Sreekumar et al. [27], examining 16 benign, 12 loca-
lized prostate cancer, and 14 metastatic prostate cancer
tissues by metabolomics using a tissue grinding method
reported that, “A subset of six metabolites including sar-
cosine, uracil, kynurenine, glycerol-3-phosphate, leucine
and proline were significantly increased on disease pro-
gression from benign to PCA [organ localized prostate
cancer] to metastatic prostate cancer.” Therefore, the
relative levels for 5 of 6 of these compounds were exam-
ined (sarcosine was below the detection limit in this
study) comparing the less aggressive T2 organ-confined
disease and the more aggressive T3 non-organ-confined
disease. All five compounds were observed to be higher
in biopsy extracts from cancer containing biopsies than
non-cancer containing biopsies, and the levels for all 5
compounds were higher in extracts from pathology T3
prostates than from T2 prostates (Figure 4 panel A).
Therefore, the results obtained using the mPREF
method were consistent with the prior published data
for these candidate biomarkers.
Additional small molecule compounds have been
reported to differ in benign vs. cancer containing pros-
tate tissues using non-mass spectrometry-based methods
of analysis including magnetic resonance spectroscopy
imaging, MRSI. These include increases in cholines, lac-
tate, and alanine, and decreases in polyamines and
citrate [28,30,33,39-42]. The levels of these compounds
were also examined in the biopsy extracts from the
mPREF method. The results (Figure 4 panel B) show
that choline could differentiate cancer from non-cancer,
and T2 from T3 disease, whereas alanine and lactate
appeared to be able to differentiate cancer from non-
cancer, but did not show a marked increase from T2 to
T3 disease. These results also demonstrate that the
mPREF method yields results consistent with previously
published data. The polyamines, putrescine, spermidine,
and spermine, and citrate had more complex patterns
(Figure 4 panel C). These compounds appeared to
increase in level in T2 prostate biopsies as compared
with non-cancer biopsies, but decreased in relative
amounts in T3 prostate biopsies.
Discussion
We report here a new method for the extraction of
molecular biomarkers from human tissue that is non-
destructive to the tissue and is compatible with down-
stream workflow including histopathology and immuno-
histochemical analysis. The method involves the simple
immersion of the tissue in 80% methanol (aqueous)
which both extracts the small molecules and fixes the
tissue. The analysis of the tissue extracts has the poten-
tial to provide for identification of molecular biomarkers
associated with any biological process in a wide array of
different tissue types. The method is compatible with
small tissue specimens such as are obtained by needle
biopsies and therefore has potential utility for clinical
practice.
Histology is the gold standard for classifying disease
and assigning prognostic grade, particularly in oncology.
The direct examination of the architecture of intact tis-
sue sections by pathologists remains powerful in classi-
fying disease, however the data generated is usually
qualitative, or semi-quantitative and the methods for
preparing histological sections can be limiting for some
downstream analyses. Studies of precision in histology
have shown that scoring is generally consistent, how-
ever, there is not always full agreement across different
laboratories [43-46]. Analysis of molecular biomarkers
provides for the possibility of quantitative measurements
to augment histology in the characterization of disease.
Innovations intended to improve biomarker detection
must take into account several factors. Biomarkers origi-
nating from tissues have oftenp r o v e nd i f f i c u l tt od i s -
cover in blood because of the dilutive factor. For
example, the most frequently used biomarker for the
early detection of prostate cancer, PSA, is not routinely
seen in proteomics discovery studies in blood from
prostate cancer patients because of its low levels. To
increase the probability of biomarker discovery, the clo-
ser in proximity one can get to the diseased tissue, the
more concentrated will be disease specific proteins, pep-
tides, nucleic acids, and metabolites. The mPREF
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Figure 3 Alanine levels as a function of percent tumor in
biopsies. The percent tumor in the cancer containing biopsies was
determined by dividing the length of tumor by length of the core.
The scaled alanine ion counts were determined as described in
Materials and Methods.
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Figure 4 Relative levels of metabolites from alcohol extracts of biopsies using the mPREF method categorized by prostatectomy
pathology class. Box and whisker plot distributions; box lower quartile to the upper quartile; whiskers, minimum and maximal values without
outliers; line, median value. x-axis categories: T2, pathology stage T2, organ-confined disease; T3, pathology stage T3, non-organ-confined disease;
neg, biopsy did not contain tumor; pos, tumor present in biopsy. y-axis: relative amount based on mass spectrometry ion counts.
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Page 7 of 12method described in this study addresses many of the
issues for the discovery of biomarkers and their transla-
tion to clinical practice. It is compatible with the long
established diagnostic and prognostic histology-based
methods, and IHC and FISH can still be performed on
the paraffin embedded tissue. The small molecule bio-
markers appear to reflect meaningful biological differ-
ences amongst tumors, and assays for these classes of
molecules can be developed that are cost effective, high
throughput, and highly accurate.
The use of alcohols as tissue fixatives is not new to
histology and has been recently described as an alterna-
tive to formaldehyde-based fixatives [8-10]. We have
demonstrated that alcohol fixation of prostate biopsies
using the mPREF method produces tissue histology
slides that can be readily read for the presence or
absence of cancer (Figure 2). In addition, IHC with the
PIN4 cocktail stain demonstrated good resolution of
basal cells and basal keratin in normal prostate glands.
In prostatic adenocarcinoma, basal cells and basal kera-
tin were absent while racemase was detected in the
cytoplasm. Other IHC stains will need to be tested
empirically to determine their compatibility with the
mPREF method. It is recognized that any change of fixa-
tion procedure has the potential to change the appear-
ance of the tissues and that a larger number of tissues
will need to be examined before general utility can be
validated. The drivers for any change in procedures are
related to the strength of the utility of any new biomar-
kers for the classification of disease. It was not the pur-
pose of this study to extensively validate the histology
and staining characteristics of alcohol vs. formalin as a
fixative for prostate biopsies. We recognize that most
pathologists are trained using formalin fixed tissues,
however, pathologists must also read cytology, hemato-
pathology smears and cryosections, which are frequently
fixed in aqueous alcohol. We anticipate the formation of
a study group of interested pathologists to share slides
and more formally evaluate this method’s acceptability
for diagnosis and grading of disease.
The primary goal of this work was to describe a new
method for the analysis of molecular biomarkers from
human tissue that allows for histopathology to be per-
formed in the same exact tissue. In addition, although
the numbers of samples analyzed by mass spectrometry
was limited in number, the mPREF method produced
data that is consistent with published reports for candi-
date biomarkers for prostate cancer. Metabolite candi-
date biomarkers previously identified using a tissue
grinding method and reported to increase in the pro-
gression of prostate cancer [27] also showed increased
levels with the mPREF method when comparing cancer
vs. non-cancer. The levels of these candidate biomarkers
were also increased in more aggressive non-organ-
confined (T3) disease, vs. the less aggressive organ-con-
fined (T2) disease (Figure 4A). Other compounds also
previously reported to be increased in prostate cancer
[28,30,39-41], were also observed to be increased in can-
cer containing biopsies using the mPREF method (Fig-
ure 4B). The relatively small numbers of prostate biopsy
extracts analyzed for metabolite profiles in this study
precluded an in depth statistical analysis, however,
further experiments are planned to investigate these
results in more detail.
In this study, 82 compounds were observed to
increase in cancer vs. non-cancer biopsy extracts. Eigh-
teen of the 20 common amino acids and a number of
long chain fatty acids and phospholipids were increased.
Analysis of the amino acids showed that the increase in
the levels of these compounds is not directly related to
the percent of tumor in the biopsy (Figure 3). It is possi-
ble that the metabolite levels have a degree of a zone
e f f e c ts h o w i n ga ni n c r e a s ei na m o u n ti na r e a sc l o s et o
histopathologically confirmed tumor. The compounds
with the highest fold increases observed (4-6 fold) were
cysteine, dihomo-linoleate, docosapentaenoate, N-acety-
laspartate, N-acetylglucosamine, uracil, xanthine, and 1-
stearoyl-glycerophosphoinositol. It is difficult to know
which of the compounds are increased as a result of a
general higher metabolic rate in more rapidly dividing
cells, and which, if any, compounds represent changes
in metabolism specifically associated with the oncogenic
process. With regard to the potential utility of these
types of changes, it has been demonstrated that the
expression of cell proliferation-related genes has prog-
nostic value for cancer disease progression [47], and it
will be of interest to determine in later experiments
which of the metabolites may have similar utilities.
The polyamines have been well studied as biomarkers
in oncology [30,41,42]. In cancers of non-prostatic ori-
gin, polyamines are increased, yet, as a differentiated
function in the prostate, the polyamines decrease in
prostate cancer as the tissue becomes de-differentiated.
In this study, the polyamines were observed to be the
lowest levels from the highest grade cancer (T3) con-
taining biopsies (Figure 4C). This is consistent with
polyamines decreasing in prostate cancer, however, the
polyamines were higher in pT2 cancer containing biop-
sies as compared with non-cancer containing biopsies.
With the notable exception of genomic DNA-based
analysis, the discovery and performance of molecular
biomarkers is highly dependent upon clinical sampling,
processing, and storage [48-50]. In this study, we
describe the mPREF method for prostate needle biopsy
specimens obtained from fresh prostate tissues following
prostatectomy. The future translation of this work to
clinically relevant studies will be to include biopsies
obtained in vivo using TRUS guided trans-rectal biopsy
Shuster et al. BMC Clinical Pathology 2011, 11:14
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Page 8 of 12procedures. The use of image guided small core needle
biopsies is likely to continue to increase while excisional
biopsies decrease in part because the latter are more
invasive, can cause more scarring and deformation, and
require use of the operating room, the most expensive
location in a hospital [51]. The use of core needle biop-
sies for molecular testing such as mutational analysis to
identify therapeutic targets provides a new rationale
both for initial diagnosis and for repeat core needle
biopsies to monitor therapy. Examples include EGFR
mutation analysis in lung cancer [52] and HER-2 in
breast cancer [53]. The mPREF method described in
this study should be widely applicable to a variety of tis-
sues. The approach described has no inherent limita-
tions for tissue type or disease state. While providing a
method for quantitative analysis of small molecules, it is
also compatible with histology, mutational analysis,
RNA expression, immunohistochemical analysis, and
other in situ methods.
Conclusions
This paper describes a simple method, mPREF, for the
extraction and analysis of small molecular weight bio-
markers from tissue specimens that is non-destructive
to tissue and is compatible with downstream histology
analysis, such that histopathology and biomarker analy-
sis can be performed on the same exact tissue. The
method is compatible with clinical biopsies without
undue interruption in clinical practice for pathology.
Methods
The mPREF method allows for extraction and measure-
ment of low molecular weight biomarkers and for his-
tology to be performed on exactly the same portion of
tissue. A summary diagram of the mPREF method is
shown in Figure 1.
Biopsies
Eight post-operative prostates were obtained from con-
sented subjects for inclusion in a biorepository approved
by the Institutional Review Board at Eastern Virginia
Medical School. The prostates were removed surgically
as primary treatment for prostate cancer. The clinical
pathology characterizations of the prostates used in this
study are shown in Table 2. Needle biopsies were taken
from the prostates ex vivo with an 18 gauge core needle
biopsy gun. The needle biopsies were taken in a manner
to follow, as closely as possible, the sampling pattern
utilized for an in vivo 12-core biopsy sampling protocol.
The peripheral zone is selectively oversampled, with left
and right lateral and medial biopsies obtained from
apex, mid-, and base of the prostate. The cores routinely
obtained were 0.9-1.2 cm in length and weighed
approximately 5-6 mg. A total of 96 prostate biopsies
were obtained.
Method of Biopsy Tissue pre-Fixation, Fixation, and post-
Processing
Each prostate needle biopsy core was placed immedi-
ately into a separate 1.8 ml vial (Thermo Scientific
#375418) containing 1.0 of 80:20 vol/vol, methanol:
water. No buffers were used in this formulation so as
not to interfere with later downstream sample concen-
tration and mass spectrometry analysis. The lids were
screwed tightly onto the vials to limit evaporation, and
the biopsy cores were fixed in the aqueous alcohol solu-
tion at room temperature, without shaking, for 24 hr.
The following day, cores were transferred to a commer-
cially available non-formaldehyde-based fixative, UMFIX
(Sakura Finetek USA, Inc., Torrance, California), until
processed. This commercial fixative is an alcohol based
fixative. Biopsies were processed on a Sakura Express ×
50 automated processor with an approximate run time
of 1.5 hrs. Tissue was embedded immediately following
processing. Histology sections were prepared using the
following technique. Blocks are faced, and placed in a
freezer to chill. A smooth block of ice is prepared to
receive the chilled blocks. Paper toweling is spread
evenly over the ice and saturated with a solution of
ammonia water (900 ml water: 30 ml ammonium
Table 2
Prostatectomy
Reference Number
Pathology
Gleason
Pathology
Stage
Margin
Status
Biopsy Positive Cores Selected for
Small Molecule analysis (n)
Biopsy Negative Cores Selected for
Small Molecule analysis (n)
21 4+3 = 7 pT2aNxMx negative 1 2
28 3+4 = 7 pT3aNxMx negative 1 1
33 3+3 = 6 pT2cNxMx negative 2 2
34 3+4 = 7 pT2cN0Mx negative 2 1
41 4+5 = 9 pT3aN0Mx multifocal 2 2
42 3+4 = 7 pT2cN0Mx negative 2 2
44 3+4 = 7 pT3aN0Mx focal 2 2
51 4+3 = 7
(tert 5)
pT3bN0Mx multifocal 2 2
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Page 9 of 12hydroxide). Blocks are soaked on the saturated toweling
for 1 hour. Biopsies are sectioned at 4 microns, two sec-
tions per level, with three levels placed on each slide.
One slide is stained with hematoxylin and eosin by rou-
tine methods, and one is retained for
immunohistochemistry.
Immunohistochemistry
PIN-4 pre-diluted cocktail (P504S, HMW Cytokeratins,
and p63; Cat # PPM 225DS) was purchased from Bio-
care Medical, Concord, CA. The Ventana BenchMark
XT automated stainer was used to process the samples.
Metabolomic analysis
Fourteen cancer containing cores, and 14 patient
matched non-cancer containing cores were selected for
metabolomic analysis of the alcohol fixatives (see Table
2). For the cancer containing cores, 7 were from patholo-
gic stage T2 (organ confined disease) prostates and 7
from stage T3 (non-organ-confined disease) prostates.
Metabolomic analysis of the biopsy alcohol extracts was
performed using a commercial services supplier (Metabo-
lon, Durham, NC), and detailed methods, including sam-
ple preparation, instrumentation, conditions for mass
spectrometry (liquid chromatography/tandem mass spec-
trometry in positive and negative ion modes, and gas
chromatography/mass spectrometry), peak data reduc-
tion, and assignment of peaks to known chemical entities
by comparison to metabolite library entries of purified
standards, have been previously described [54,55], with
the modification that the sample extracts were first con-
centrated to dryness by evaporation of the 80% methanol:
water solvent prior to analysis. The data output from this
global metabolomics method is relative ion counts; the
absolute quantitative amount of metabolites in a sample
is not determined using this method. Instrument variabil-
ity was determined by calculating the median relative
standard deviation (RSD) for internal standards that were
added to each sample prior to injection into the mass
spectrometers. The median instrument variability was
4%. Overall process variability was determined by calcu-
lating the median RSD for all endogenous metabolites
(non-instrument standards) present in 100% of technical
replicates of pooled experimental samples. The median
process variability was 10%. Comparisons of relative ion
counts were made following log transformation and
imputation with minimum observed values for each com-
pound. Each biochemical was re-scaled to have median
equal to 1. Matched-pairs t-tests were used to identify
biochemicals that differed significantly between groups.
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